Adocia : All claims dismissed in second phase of arbitration with Lilly
>All claims dismissed by both parties - Adocia this morning communicated the ruling by the American Arbitration Association Tribunal regarding the dispute between it and its former partner Eli Lilly. The decision boils down to the dismissal of the compensation claims by both parties. To recap, Adocia had submitted claims for compensation from Lilly relating to the misappropriation and misuse of its confidential information and discoveries. Lilly subsequently filed cou...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.